Invasive Margin Tissue-resident Macrophages of High CD163 Expression Impede Responses to T Cell-based Immunotherapy

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2023 Mar 13

PMID 36914207

Authors

Marit J van Elsas

Camilla Labrie

Anders Etzerodt

Pornpimol Charoentong

Jordi J C van Stigt Thans

Thorbald van Hall

Sjoerd H van der Burg

Affiliations

Soon will be listed here.

Abstract

Background: Primary and secondary resistance is a major hurdle in cancer immunotherapy. Therefore, a better understanding of the underlying mechanisms involved in immunotherapy resistance is of pivotal importance to improve therapy outcome.

Method: Here, two mouse models with resistance against therapeutic vaccine-induced tumor regression were studied. Exploration of the tumor microenvironment by high dimensional flow cytometry in combination with therapeutic settings allowed for the identification of immunological factors driving immunotherapy resistance.

Results: Comparison of the tumor immune infiltrate during early and late regression revealed a change from tumor-rejecting toward tumor-promoting macrophages. In concert, a rapid exhaustion of tumor-infiltrating T cells was observed. Perturbation studies identified a small but discernible CD163 macrophage population, with high expression of several tumor-promoting macrophage markers and a functional anti-inflammatory transcriptome profile, but not other macrophages, to be responsible. In-depth analyses revealed that they localize at the tumor invasive margins and are more resistant to Csf1r inhibition when compared with other macrophages. studies validated the activity of heme oxygenase-1 as an underlying mechanism of immunotherapy resistance. The transcriptomic profile of CD163 macrophages is highly similar to a human monocyte/macrophage population, indicating that they represent a target to improve immunotherapy efficacy.

Conclusions: In this study, a small population of CD163 tissue-resident macrophages is identified to be responsible for primary and secondary resistance against T-cell-based immunotherapies. While these CD163 M2 macrophages are resistant to Csf1r-targeted therapies, in-depth characterization and identification of the underlying mechanisms driving immunotherapy resistance allows the specific targeting of this subset of macrophages, thereby creating new opportunities for therapeutic intervention with the aim to overcome immunotherapy resistance.

Citing Articles

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.

Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer.

Yuceer R, Aydin S, Gelir I, Koc T, Tuncer E, Ucar M Diagnostics (Basel). 2025; 15(2).

PMID: 39857116 PMC: 11764053. DOI: 10.3390/diagnostics15020232.

Cellular plasticity and non-small cell lung cancer: role of T and NK cell immune evasion and acquisition of resistance to immunotherapies.

Mestiri S, Sami A, Sah N, El-Ella D, Khatoon S, Shafique K Cancer Metastasis Rev. 2025; 44(1):27.

PMID: 39856479 DOI: 10.1007/s10555-025-10244-8.

Optimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC.

Chen Y, Chen A, Hong R, Huang B, Pirooznia M Sci Rep. 2024; 14(1):31382.

PMID: 39733163 PMC: 11682295. DOI: 10.1038/s41598-024-82903-9.

Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer.

Lauwers Y, De Groof T, Vincke C, Van Craenenbroeck J, Jumapili N, Barthelmess R Proc Natl Acad Sci U S A. 2024; 121(52):e2409668121.

PMID: 39693339 PMC: 11670109. DOI: 10.1073/pnas.2409668121.

References

Berry S, Giraldo N, Green B, Cottrell T, Stein J, Engle E . Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science. 2021; 372(6547). PMC: 8709533. DOI: 10.1126/science.aba2609. View

Zhu Y, Herndon J, Sojka D, Kim K, Knolhoff B, Zuo C . Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Immunity. 2017; 47(2):323-338.e6. PMC: 5578409. DOI: 10.1016/j.immuni.2017.07.014. View

Theruvath J, Menard M, Smith B, Linde M, Coles G, Dalton G . Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat Med. 2022; 28(2):333-344. PMC: 9098186. DOI: 10.1038/s41591-021-01625-x. View

Zhang Q, Liu L, Gong C, Shi H, Zeng Y, Wang X . Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One. 2013; 7(12):e50946. PMC: 3532403. DOI: 10.1371/journal.pone.0050946. View

Thoreau M, Penny H, Tan K, Regnier F, Weiss J, Lee B . Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site. Oncotarget. 2015; 6(29):27832-46. PMC: 4695029. DOI: 10.18632/oncotarget.4940. View

Yang C, Wei C, Wang S, Shi D, Zhang C, Lin X . Elevated CD163/CD68 Ratio at Tumor Invasive Front is Closely Associated with Aggressive Phenotype and Poor Prognosis in Colorectal Cancer. Int J Biol Sci. 2019; 15(5):984-998. PMC: 6535793. DOI: 10.7150/ijbs.29836. View

Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J . Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014; 5:75. PMC: 3942647. DOI: 10.3389/fphys.2014.00075. View

Ensan S, Li A, Besla R, Degousee N, Cosme J, Roufaiel M . Self-renewing resident arterial macrophages arise from embryonic CX3CR1(+) precursors and circulating monocytes immediately after birth. Nat Immunol. 2015; 17(2):159-68. DOI: 10.1038/ni.3343. View

Lima L, Oliveira D, Tavares A, Amaro T, Cruz R, Oliveira M . The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure. Urol Oncol. 2013; 32(4):449-57. DOI: 10.1016/j.urolonc.2013.10.012. View

10.

Hirai K, Sasahira T, Ohmori H, Fujii K, Kuniyasu H . Inhibition of heme oxygenase-1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice. Int J Cancer. 2006; 120(3):500-5. DOI: 10.1002/ijc.22287. View

11.

Ahmad I, Dafferner A, OConnell K, Mehla K, Britigan B, Hollingsworth M . Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2021; 13(9). PMC: 8125955. DOI: 10.3390/cancers13092264. View

12.

Sharma A, Seow J, Dutertre C, Pai R, Bleriot C, Mishra A . Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell. 2020; 183(2):377-394.e21. DOI: 10.1016/j.cell.2020.08.040. View

13.

Petrillo M, Zannoni G, Martinelli E, Pedone Anchora L, Ferrandina G, Tropeano G . Polarisation of Tumor-Associated Macrophages toward M2 Phenotype Correlates with Poor Response to Chemoradiation and Reduced Survival in Patients with Locally Advanced Cervical Cancer. PLoS One. 2015; 10(9):e0136654. PMC: 4559430. DOI: 10.1371/journal.pone.0136654. View

14.

Santegoets S, Duurland C, Jordanova E, van Ham V, Ehsan I, Loof N . CD163 cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer. J Immunother Cancer. 2020; 8(2). PMC: 7418847. DOI: 10.1136/jitc-2020-001053. View

15.

Beyranvand Nejad E, Labrie C, Abdulrahman Z, van Elsas M, Rademaker E, Kleinovink J . Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy. J Immunother Cancer. 2020; 8(2). PMC: 7467529. DOI: 10.1136/jitc-2020-001326. View

16.

Pinto A, Paolicelli R, Salimova E, Gospocic J, Slonimsky E, Bilbao-Cortes D . An abundant tissue macrophage population in the adult murine heart with a distinct alternatively-activated macrophage profile. PLoS One. 2012; 7(5):e36814. PMC: 3349649. DOI: 10.1371/journal.pone.0036814. View

17.

Zhu Y, Knolhoff B, Meyer M, Nywening T, West B, Luo J . CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014; 74(18):5057-69. PMC: 4182950. DOI: 10.1158/0008-5472.CAN-13-3723. View

18.

Gusak A, Fedorova L, Lepik K, Volkov N, Popova M, Moiseev I . Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations. Cancers (Basel). 2021; 13(22). PMC: 8616219. DOI: 10.3390/cancers13225676. View

19.

Sade-Feldman M, Jiao Y, Chen J, Rooney M, Barzily-Rokni M, Eliane J . Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017; 8(1):1136. PMC: 5656607. DOI: 10.1038/s41467-017-01062-w. View

20.

ORourke S, Dunne A, Monaghan M . The Role of Macrophages in the Infarcted Myocardium: Orchestrators of ECM Remodeling. Front Cardiovasc Med. 2019; 6:101. PMC: 6685361. DOI: 10.3389/fcvm.2019.00101. View